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Phy~iological inht biters were tested for their in vitro interaction with neutrophil protemase 3 (PR3). The major plasma protemase inhibitor of PR3 
is =tAT. We have developed a radioimmunoa~ay (RIA) for quantitative detection of PR3--CtlAT complexes formed in rive in inflammatory 
exudates such as synovtal fluid and plasma from patients with sepsis. Levels ofPR3-a~AT complexeb correlated significantly with levels of human 
nemrophtl elastase (HNE)--~tAT complexes. Thus, in vtvo a~AT not only proteet~ against excessive HNE activity, but also against excessive PR3 
activity. 
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1, INTRODUCTION 
Proteinase 3 (PR3) is a 29 kDa serine proteinase 
which is biochemicaliy distinct from human neutrophil 
elastase (HNE) and cathepsin G [1]. PR3 is at least as 
prominent in neutrophil azurophilic granules as HNE, 
and comparison of the active site regions of both en- 
zymes reveals a strong homology [2]. We have recently 
compared the substrate and inhibitor reactivity of PR3 
and HNE and revealed significant differences in the 
extended substrate binding sites of both enzymes [3]. 
PR3 degrades a broad spectrum of extracellular matrix 
proteins [4,5], induces emphysema upot~ intratraeheal 
instillation in hamsters [1], and is the target antigen of 
Wegener's granulomatosis (WG) autoantibodies [6-8]. 
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zoate; Nva, norvalme; PBS, phosphate-buffered sahne; PD$, 4,4'- 
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teinase 3, SBzl, thiobenzyl =st=r, Sue, suecinyl; RA, rheumatoid arthri- 
tis; RIA, radioimmunoassay; SF,~ynovial f uid; WG, Wegener's gran- 
ulomatosin; Z, benzyloxyearbonyl. 
The most important physiological inhibitor of PR3 is 
0~l-antitrypsin (cx~AT) [5]. 
In the present study we have determined the in vitro 
association constants for PR3 with several physiologi- 
cal inhibitors, and compared the values with those pre- 
viously reported [5]. We have also developed a radioim- 
munoassay (RIA) for the detection of PR3--~tAT com- 
plexes in plasma and in inflammatory tissue exudates to 
investigate the in rive significance of inactivation of 
PR3 by 0fiAT. 
2. MATERIALS AND METHODS 
2.1. Purification of PR3 
PR3 was purified accordmg to the method of Kao et al. [1] from 
neutrophil granule emract as described [3]. 
2.2. Active #ire tttrattons 
Bovine pancreatic trypsin, chymotrypsm, andp-nitrophenyl 4'-$ua- 
mdmobenzoatc (NPGB) wer~ purehas~l from Sigma Chemical Co., 
St. Louis, Me. Human plasma stLAT and at2-macroglobin (0t_,M) were 
from Athens Research and Technology Inc., Athens, GA. ,r:-Antiplas- 
rain (strAP), ctj-antichymotrypsm (~xlAC"T), and antithrombin Il l  
(ATIII) were obtained from Calbioehem, San Diego, CA. e l  inhibitor 
(Cl-mh) was a kind sift From Behnn s Werke AG, Marburg Ger- 
many. Sabstrates Z-Ars-SBzL Suc-VaI-Pro-Phe-pNA, and Boc-Ala- 
Ala-Nva-SBzl were synthesized as previously described [9-111. Oxida- 
tion of 0ttAT (cttAT-ox) was performed as described [12]. Bovine 
trypsin was titratod with NPGB [13] and was found to be 70% active 
with respect o total proteins. The trypsin solution was ~ as a 
primary, s'tandard to delerrnine the active inhibitor concentration of
a,AT. A constant amount of trypsin (0.12 aM) was incubated with 
various amount~ of =~AT (0.01--0.2/.tM) in 0,5 ml of 0.05 M Trin-HCl, 
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pH 8.0, at 25°C for 5 lain, and then a 1091 aliquot was added to 2.175 
ml of buffer containing 8% dimethylsulfoxlde (DMSO), 0 34 mM of 
4,4'-dtthiodipyridmc (PDS)and 0.095 mM of Z.Arg-SBzl. The resid- 
ual trypsin activity wan monitored at 324 nm. The active inhibitor 
concentration was determined frona the plot of residual trypsin activity 
w atAT concentration. The 0qAT solution was used as a secondary 
standard to determine the active enzyme concentration of PR3 and 
chymotrypsin using Boc-Ala-Ala-Nva-SBzl and Suc-Val-Pro-Phe- 
pNA a~ substrat¢~. 
2.3. htteractwn el ph),MoIoew mhtbitors with PR3 
Assocmtlon rate constant of PR3 with %AT was measured under 
second-order condmons. Equimolar concentration~ of PR3 and ~AT 
(13.4 aM) were incubated in 0.5 M NaCI, 0 1 M HEPES, pH 7.5, for 
vmtoas ~,eriodn of ame. Residual activity of PR3 was deten~mned by
the addmon of PDS (0 34 raM) and Boe-Ala-Ala-Nva-SBzl (0 1! 
raM), and measured spectrophotometncally at 324 nm. q'hl~ associa- 
tion was al~o measured by competition experiments using active site 
thrated chymotrypsm as the ~econd enzyme besides PR3 [14,15]. 
Equivalence tttratmn of r~,M to PR3 was performed u: the presence 
of ~AT.  A constant amount of PR3 (152 nM) was incubated with 
increasing amount~ of ~.,M ,n 0.33 ml of 0.5 M NaCI, 0.1 M HEPES, 
pH 7.5, at 25°C for 10 rain. Then 203tl ofa~AT (1 36/..tM) was added 
to the reaction mixture and incubated for another 5mm to inhibit the 
free PR3. Finally, an ahquot of 0.25 ml was added to 2.175 ml buffer 
containing PBS (0.34 raM) and Boc-Ala-Ala-Nva-SBzl (0.1 mM) to 
measure ~aM bound PR3 activity. This experiment was used to deter- 
mine the ~2M coneentiauon a~umm~ the molar binding ratio of PR3 
to ~:M is I'1 [5,16]. The a~soeiation rate constant of PR3 with ~,M 
was measured compeutively with ~etAT [14,16]. PR3 (I 1.5 nM) was 
added to a mixture of ~t,M (12.8 nM) and various amounts of chAT 
(11.5-57.6 nM) in 0.5 M NaCl, 0 1 M HEPES, pH 7.5, at 25°C. After 
I0 ram, 1501,'1 of 5 iaaM PDS and 25M1 of 10 mM Boc-Ala-Ala-Nva- 
SBzl was added, and the residual activity of PR3 bound to ~,M was 
n~teasured at 324 nm. The association rate constant ofg,M to PR3 was 
calculated according to the method escribed previously [14,16]. 
I nte~ action of PR3 v, it h ~¢ tACT, ~t:AP, ATI 11, C 1 -inh, and g tAT-ox 
was determined under similar eoqditions in a 1:10 molar exce,~,, of 
inhibitor. 
2.4. Radiolabethtg ofMAb A TI5 
For u~¢ in the RIA MAb ATI5 (directed against eomplexed ~Aq') 
[171 was labeled with ~"~I (Radiochemical Centre, Ame~ sham, UK) by 
the lodo-gen methcd [18] at a specific activity of 0.30 MBq per/ag of 
protein. 
2.5. Patients 
Two groups of patients with mflarnmator~ disorders were selecteca 
lbr this study. The first group consisted of 18 patient~ with rheumatoid 
arthritis (RA), visiting the outpatient chnm of the Daniel den Hoed 
Clinic in Rotterdam, The Netherlands. All patients fulfilled the ARA 
criteria for RA [19]. The patients were part era larger group that was 
studied with re~pect o several inflammatory parameteis, including 
ncutrophil activation and detemiination f HNE-=tAT complexes in
their synovial fluid (SF) [17]. 
The second group consisted of 14 patient~ who were admitted to the 
Intensive Care Unit (ICU) of the Free University Hospital in Amster- 
dam after clinical diagnosis of severe sepsis. Previously, the levels of 
FINE--a~AT complexes had been detected in the same plasma samples 
of these patmmh [20]. Patients were selected to cover a range of differ- 
ent SF/plasma levels of HNE--a~AT complexes. 
2.6. SF ~ampte~ 
SF samples were taken from the knee joint at therapeutical indica- 
tion. The SF was a,,pwated rote a plastic syringe and immediately 
transferred to a s'.hcontzed Vacatamer tube, comaming 0.05% (w/v) 
Polybrene and 10 mM EDTA to prevent in vitro activation of the 
complement and contact ~ystem. The s,tmple~ were stored at -70°C 
untd the tests were performed 
2.7 Sepsis plasma samples 
Blood from 14 patients with sepsis was obtained, collected and 
processed as described [20]. Plasma was divided into aliquots and 
~tor, ~ in polystyrene tubes at -70°C until the tests were perfornaed. 
2 8. RDI for the detection ofPR3--a~A T attd HNE--~jAT complexe~ 
[mmunoglobuhn-enriched fractions of rabbit antiserum against 
HNE (RIA for iqNE-~ztAT) and aseitic fluid of MAb 12.8 directed 
against PR3 (RIA for PR3-czzAT ) [6], were prepared by 50% amino- 
mum sulphate precipitation and were coupled to CNBr-aetivated 
Seplaamse (20 mg ofprotein to 1 g of Sephaiose). The Sepharose bead', 
¢eere suspended in PBS containing 10 mM EDTA, 0.1% (v/v) Tween- 
20, 0.05% (w/v) Polybrene (Jan~sen Chit'men, Beetle, Belgium), 1.5 
mM NaNa, 10 mM benzamtdine (Janssen Chimica, Beerse, Belgium) 
and 0 01% (w/v) soybean trypsin lahlbRor (SBTI, BDH Biochemtcals 
Ltd., Peele, UK), pH 7.4, at concentratlon~ of 2 mg/ml (Sephaiose/ 
labbit anti-HNE) wad 4 mffml (Sepharose/MAb 12 8). Sepharose 
~uspensions el" 0.3 ml (RIA for I-INE-a~AT) and of 1.0 ml (RIA for 
PR3-,~'~AT) were incubated in 2 ml polystyiene tubes foi 4 h by 
head.over-head rotation at room temperature wuh samples diluted in 
PBS-0.1% (v/v) Tween-20 (50 ,ul of SF samples (1:25), and ~epsis 
plasma ~amples (1:5)). Sepharose heads were then washed with PBS 
(5 times w~th 1.5 ml)and incubated for 16 h at room temperature w~th 
50,ttl of[ml]MAb AT I 5 (approximately 2-3 ng) together with 0.5 ml 
o1" PBS, 0.1% (v/v) Tween-20 and 5% (v/v) bovine ~elum. Subse- 
quently, the Sepharo,.e was washed whh PBS (4 times wah 1.5 ml) and 
the bound radioactivity was measured. Results were expressed as 
percentage binding of the labeled antibodms added. Levels of PR3- 
0qAT and HNE-atAT complexes were calculated by using a standard 
do~-response curve of preformed complexes prepared by incubating 
purified active site tttrated PR3 and HNE with an excess of pooled 
hulnan plasma. Further details on the assay for the detection of HNE- 
a~A'l" complexes have been described el~ewhe,  [20] 
3. RESULTS 
3.1. Interaction o f  physiological #~hibttors with PR3 
The in teract ion  oFPR3 with cx~AT and  cx2M was  mon-  
i tored us ing Boc -A la -A la -Nva-SBz l  as the subst ra te  
(Tab le  I). The  assoc ia t ion  rate constants  for  PR3  with 
ct~AT was measured  under  second-order  cond i t ions  and  
by COlr~petition exper iments ,  and  were found  to be 4.4 
× 100 and 5.7 ,'< 10 ° M -~ • s-t0 respect ively.  These va lues  
are one  order  o f  magn i tude  less than the repor ted  va lue 
o f  l iNE  (6.5 × 10 ~ M -I • s -~) and one order  o f  magla i tude 
Table I 
Association rate constant~ for the lntcr,tction of phys~ological mhlb- 
tiers with PR3* 
Inllubttor k~ (M -~ s -~) Melhod 
~-A n titrypsm 
0k,-Macroglobuha 
aj-Antichymotrypsm 
aa-Antiplasmm 
Ant~trombm 111 
el-inhibitor 
Oxidized c¢~-antitrypsin 
4,4 × 10 ~ 
5,7 × 10 ~ 
(1.1 + 0.1) × 10 7 
no inhibition** 
no inhibition*" 
no inhibition** 
no inhibmon** 
no inhibition** 
~¢¢ond-order conditions 
compctRlon experiment 
competition assay 
competition assay 
competition unsay 
competition assay 
competition a~ay 
competition assay 
*Association rate eonqants were measured in 0.5 M NaC!, 0.1 M 
HEPES, pH 7.5, and at 25aC, 
**PR3 was incubated with inlubltor in a I' 10 molar excess of inhibitor 
and no chang," in the enzyme aeuvaty was observed. 
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higher than that ofeathepsin G (4.1 x l0 s M -I . s -t) [15]. 
Using the k, values for PR3 with chAT, we determined 
the association rate constants of 0t2M to PR3 by a pre- 
viously described competition assay [14,16]. The k~ 
value for PR3 with 0~.,M was 1.1 x 107 which is 4-fold 
less than that oFHNE (4.1 x 107 M -I • s -I) and 3-fold 
higher than that ofeathepsin G (3.7 x 106 M -t • s -l) [16]. 
These association rate constants for PR3 with 0qAT or 
~z2M were consistent with the previously reported values 
by Raoet  al. [5]. 
PR3 was not inhibited by either 0hACT, 0hAP, ATIlI, 
Cl-inh, or cz~AT.ox under the conditions employed. 
3.2. Measurement of PR3--~A T complexes br a RIA 
In Fig. 1 a dose-response curve is shown that was 
obtained by testing different dilutions of pretbrmed 
PR3-cztAT complexes. These complexes were prepared 
by the addition of active site titrated PR3 either to an 
excess of purified ce~AT or to an excess of pooled i~uman 
plasma. As a cont':ol, PR3 was inactivated by DFP 
prior to incubation with either czaAT or pooled human 
plasma. The RIA appeared to be highly specific, sensi- 
tive and reproducible: as few as 0.5 nM of PR3--~tAT 
complexes could be detected by this RIA, and intra- 
assay as well as inter-assay coefficients of variation were 
less than 10%. The difference in the dose-response 
curves of PR3 mixed with either purified 0qAT or 
plasma was only slight, indicating that virtually all PR3 
added to plasma had formed a complex with its major 
inhibitor, 0hAT. In addition, these experiments indi- 
cated that an excess of irrelevant plasma proteins did 
not interfere with the detection of the PR3-czIAT com- 
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Fig. 2. Relatiomhip between levels of PR3--~2AT and I-INE--~tAT 
complexes m inflammatory fluids. In SF obtained from 18 patients 
with R.A (A), and in plasma from 14 patients with sepsis (B). PR3- 
(xtAT and HNE-gtAT complexes were detected by RIA, The levels 
of Pg3-atAT complexes were plotted against he corresponding levels 
of HN E-atAT complexes, and are ~hown on a logarithmic scale. The 
dotted line represents he weighted linear regression line. SF samples 
r = 0.94, P < 0.01; sepsm plasma samples: r = 0.88, P < 0.01. 
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Fig. 1. Detection of PR3-~LAT complexes by RIA. PR3 (2~M) was 
incubated with either 250/.d of pooled human plasma or 250/~1 20:tM 
chAT for 30 rain at room temperature. These m,xtures were diluted 
(1:20) m PBS-0.1% (v/v) Tween-20, and subsequently testcxi m 2-fold 
serial dilutions by RIA. The amounts of tile original mixtures (1.20) 
expressed as,ul tested, are indicated on the abcissa. 1/tl tehted contains 
1 nM of PR3-g~AT complexe~ (A,o). Control experinaents were per- 
formed by inh~b~tlnl~ PR3 with DFP (20/.tM) prior to incubation with 
either plasma or gtAT. In these control experiments 1 l t l  t~.~ted con- 
tains I nM of DFP treated PR3 (±,=). Results are expressed as~r- 
centag¢ of binding of the labeled antibodies added. The experiment 
shown is representative of 5experiments performed. The intra-a~say 
coefficient of variation was less than 10%. 
plexes. In 01asma to which DFP-treated PR3 was 
added, a response corresponding to approximat¢l), ! 
nM of PR3--a,AT complexes was measured. This re- 
sponse was also observed in plasma without addition of 
PR3 (not shown), and apparently was due to the pres- 
ence of low levels of  PR3--~tAT complexes in pooled 
normal plasma (see below). Preincubation of plasma 
with methylamme to inactivate ~2M, did not signifi- 
cantly alter this dose-response curve, which indicated 
that the formation of PR3--~2M did not detectabiy nflu- 
ence the formation of PR3--~,AT complexes in plasma. 
3.3. Detection of  PR3--g~A T complexes formed in vivo 
in SF fi'om arthritic joints and in plasma from pa- 
tients with sepsis 
To investigate whether formation of PR3--g~AT com- 
plexes also occurs in vivo, we tested SF obtained from 
18 patients with RA, and plasma samples from 14 pa- 
tients with sepsis. In Fig. 2A the levels of PR3--~x~AT 
complexes in these SF samples are plotted against he 
corresponding HNE-ohAT ievei~. A strong correlation 
between these levels (r = 0.93, P < 0.01) was observed. 
In addition, in plasma samples of  patients with sepsis, 
i19 
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PR3--ottAT complexes could be detected and correlated 
significantly with HNE-~t~AT levels (r = 0.88, P < 0.01) 
(Fig. 2B). Levels of PR3-cx~AT complexes in plasma 
from healthy donors varied from 0.5-2.5 riM, compara- 
ble to the levels of HNE---~AT complexes [20]. Thus, 
also under (patho-)physiological conditions in r ive 
~AT appears to be an inhibitor of PR3. 
4. D ISCUSSION 
Prevention of excessive tissue damage by extracellu- 
lar elastinolytic enzymes requires neutralization of these 
enzymes by proteinase inhibitors. We report here on the 
interaction of PR3 with physiological proteinase inhib- 
itors. We obtained association rate constants that sug- 
gest that both ~tAT and cx2M are effective inhibitors of  
PR3 in vitro. Our kinetic data are in agreement with 
those previously reported by RaG et al. [5]. In addition, 
detection of PR3-cx~AT complexes in the SF of RA  
patients and in plasma of  patients with sepsis indicates 
that also in vivo ~tAT plays an important role as an 
inhibitor of PR3. The detection of equal amounts of  
PR3-cx~AT complexes in plasma and in methylanaine- 
treated plasma indicated that, compared to tz~AT, tx_~M 
is of minor importance as an inhibitor of  PR3 in plasma. 
We have investigated the interaction of PR3 with 
other plasma proteinase inhibitors, such as =~ACT, 
~2AP, ATII I ,  and Cl-inh. No inhibition of PR3 was 
detected by these inhlbitors. Alsoo ~x~AT-ox did not in- 
hibit PRL  which can be of  importance in the microenvi- 
ronment of activated neutrophils where 0qAT can be 
inactivated by reactive oxygen derivatives [21]. 
Patients with t~tAT deficiency, an autosomal reces- 
sive disorder characterized by reduced serum levels of  
functional ~xtAT, are particularly susceptible to the de- 
velopment of emphysema [22]. It is generally assumed 
that these patients produce insufficient ~x~AT to protect 
the alveolar walls from exposure to HNE,  which results 
in progressive destruction of lung tissue, culminating in 
pulmonary emphysema [23]. Our finding that 0hAT is 
also the major plasma inhibitor of PR3 suggests that, 
in g~AT-defieient patients, in addition to HNE, PR3 
may be an important factor in the development of em- 
physema. This is further emphasized by the previous 
observations that PR3 is even more abundant in neutro- 
phils than HNE [2], and because it displays strong 
elastinolytic and emphysema-causing properties [1,4]. 
PR3 is the antigen recognized by autoantibodies (C- 
ANCA)  that circulate in the blood of patients with WG 
1"6-8]. The possible role of  these C-ANCA in the patho- 
genesis of WG is still unclear. In vitro, these autoanti- 
bodies induce primed PMN to degranulate [24]. Re- 
cently, we have obtained evidence that binding of  C- 
ANCA to PR3 prevents the enzyme from being inac- 
tivated by =~AT [25]. The resulting unbalanced activity 
of  PR3 may contribute to inflammatory tissue damage, 
including necrosis and vasculitis. In vitro, neutrophils 
120 
release HNE upon stimulation by various agonists [26]. 
High amounts of HNE in arthritic joints indicate that 
neutrophils are activated and/or damaged in several 
arthropathies [27]. We found corresponding levels of  
PR3-~tAT and HNE-~AT in SF of RA patients, as 
well as in plasma of  patients with sepsis, suggesting that 
these complexes may serve as markers of neutrophil 
activatiort. Studies on the levels of  PR3-~jAT com- 
plexes in the plasma of WG patients and in other in- 
f lammatory diseases are now in progress. In conclusion, 
we have demonstrated that both gtAT and ~.,M are 
plasma inhibitors of PR3, and that ~tAT also in r ive 
is important for the regulation of PR3 activity. These 
inhibitors should be taken into account in the explora- 
tion of the possible role of  PR3 in different pathophys- 
iological conditions. 
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